Eric Ruderman, MD
Rheumatology · Chicago, ILNPI 1871526657
Payments from drug & device makers
Across 515 payments — averaging $927.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$97K
- UCB, Inc.$72K
- Pfizer$68K
- Novartis$60K
- Navidea Biopharmaceuticals, Inc.$38K
- Lilly USA, LLC$37K
- plus $106K from 14 others
Across 3 payments — averaging $7912.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$13K
- Swedish Orphan Biovitrum AB$8K
- NS Pharma, Inc.$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 75 | $97,415 |
| UCB, Inc. | 50 | $72,363 |
| Pfizer | 49 | $67,924 |
| Novartis | 97 | $59,992 |
| Navidea Biopharmaceuticals, Inc. | 4 | $37,530 |
| Lilly USA, LLC | 30 | $36,709 |
| E.r. Squibb & Sons, L.L.C. | 46 | $34,382 |
| Janssen Scientific Affairs, LLC | 71 | $16,016 |
| Merck | 5 | $12,075 |
| Novartis Pharma AG | 9 | $9,569 |
| Amgen(2 entities) | 12 | $8,560 |
| Eli Lilly | 4 | $8,400 |
| Gilead | 11 | $7,142 |
| Sanofi | 20 | $3,715 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,823 |
| Genentech USA, Inc. | 8 | $1,542 |
| Genentech, Inc. | 19 | $1,103 |
| Celltrion Healthcare Co., Ltd | 1 | $500 |
| GSK | 1 | $122 |
| Arcutis Biotherapeutics, Inc. | 1 | $36 |
How this compares
$477,917 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Chicago
- Manish JainChicago$36.5M
- Theodore PincusChicago$524K
- Anisha DuaChicago$284K
- Arthur MandelinChicago$270K
- Duncan MooreChicago$206K
- Joel BlockChicago$186K
- Timothy NiewoldChicago$165K
- Yvonne LeeChicago$157K
- Robert WoodrickChicago$143K
- Ailda NikaChicago$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.